FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283382900> ?p ?o ?g. }

• W4283382900 endingPage "1935" @default.
• W4283382900 startingPage "1934" @default.
• W4283382900 abstract "Background: Hodgkin lymphoma (HL) is a hematologic malignancy with a high rate of curability. However, 5 to 20% are primary refractory to treatment or relapse after achieving a complete remission (CR) and present a therapeutic challenge. Aims: Our study aims to evaluate the clinical characteristics, treatment patterns, as well as therapeutic results in patients with refractory/ relapsed HL (R/R HL) in a Tunisian center. Methods: It is a retrospective study about adult patients (<60 years old) with R/R HL, treated between January 2008 and Mars 2020 at the hematology, oncology, and radiotherapy departments of the hospital of Sfax, Tunisia. The first-line treatment was based on ABVD in favorable early stages and BEACOPP regimens in advanced stages and localized stages with a bulky mediastinal mass. The standard of care for R/R HL was salvage chemotherapy followed by autologous stem cell transplantation (ASCT) in the national bone marrow transplant center in Tunis. The date of the point is in July 2021. Results: A total of 55 patients were enrolled, which represents 25% of our series of HL managed in this period. The median age was 30 years (range 17-59), and the sex ratio was 1.3. Twenty-five patients (45%) presented with refractory disease. Among the 30 patients (55%) who relapsed, 19 patients (63%) relapsed within 12 months after achieving CR. At relapse, advanced stage, anemia, and B-symptoms were respectively recorded in 60%, 33%, and 53% of cases. Two patients died before salvage chemotherapy (CT), so 53 patients were treated. Second-line CT regimens used were Cytarabine-based regimens (DHAC/DHAP) in 74% of cases, Gemcitabine-based regimens (IGEV) in 19%, and ICE in 7% of cases respectively. IGEV was the most effective regimen to mobilize peripheral blood stem cells (69% vs 30% with Cytarabine-based regimens). A CR was noted in 61% of cases. Radiotherapy was associated with CT in 35% of cases. Only 13 patients (42% of eligible patients) benefited from ASCT. The 5-year overall survival estimate for all patients was 46%, and 5-year PFS was 41%. Chemoresistance to salvage therapy, ≥ 2 lines of salvage therapy, non-realization of ASCT, and insufficient response after treatment were predictive adverse prognostic factors (p<0.001). Summary/Conclusion: Our study showed that CR and feasibility of ASCT were lower than that reported in international studies (61% vs 76%, and 46% vs 69 to 100% respectively), which incites us to a better involvement of ASCT. Besides, the association of new therapeutic agents such as Brentuximab Vedotin should be considered in our patients with chemoresistant HL." @default.
• W4283382900 created "2022-06-25" @default.
• W4283382900 creator A5001360263 @default.
• W4283382900 creator A5001702374 @default.
• W4283382900 creator A5009180317 @default.
• W4283382900 creator A5020640294 @default.
• W4283382900 creator A5034031232 @default.
• W4283382900 creator A5035169398 @default.
• W4283382900 creator A5044694055 @default.
• W4283382900 creator A5049435131 @default.
• W4283382900 creator A5051345226 @default.
• W4283382900 creator A5051956051 @default.
• W4283382900 creator A5059218186 @default.
• W4283382900 creator A5067377366 @default.
• W4283382900 creator A5073440840 @default.
• W4283382900 creator A5075123487 @default.
• W4283382900 creator A5079606708 @default.
• W4283382900 creator A5080327314 @default.
• W4283382900 creator A5083333102 @default.
• W4283382900 creator A5091386251 @default.
• W4283382900 date "2022-06-01" @default.
• W4283382900 modified "2023-09-27" @default.
• W4283382900 title "PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER" @default.
• W4283382900 doi "https://doi.org/10.1097/01.hs9.0000851084.95453.40" @default.
• W4283382900 hasPublicationYear "2022" @default.
• W4283382900 type Work @default.
• W4283382900 citedByCount "0" @default.
• W4283382900 crossrefType "journal-article" @default.
• W4283382900 hasAuthorship W4283382900A5001360263 @default.
• W4283382900 hasAuthorship W4283382900A5001702374 @default.
• W4283382900 hasAuthorship W4283382900A5009180317 @default.
• W4283382900 hasAuthorship W4283382900A5020640294 @default.
• W4283382900 hasAuthorship W4283382900A5034031232 @default.
• W4283382900 hasAuthorship W4283382900A5035169398 @default.
• W4283382900 hasAuthorship W4283382900A5044694055 @default.
• W4283382900 hasAuthorship W4283382900A5049435131 @default.
• W4283382900 hasAuthorship W4283382900A5051345226 @default.
• W4283382900 hasAuthorship W4283382900A5051956051 @default.
• W4283382900 hasAuthorship W4283382900A5059218186 @default.
• W4283382900 hasAuthorship W4283382900A5067377366 @default.
• W4283382900 hasAuthorship W4283382900A5073440840 @default.
• W4283382900 hasAuthorship W4283382900A5075123487 @default.
• W4283382900 hasAuthorship W4283382900A5079606708 @default.
• W4283382900 hasAuthorship W4283382900A5080327314 @default.
• W4283382900 hasAuthorship W4283382900A5083333102 @default.
• W4283382900 hasAuthorship W4283382900A5091386251 @default.
• W4283382900 hasBestOaLocation W42833829001 @default.
• W4283382900 hasConcept C121332964 @default.
• W4283382900 hasConcept C126322002 @default.
• W4283382900 hasConcept C141071460 @default.
• W4283382900 hasConcept C142424586 @default.
• W4283382900 hasConcept C146357865 @default.
• W4283382900 hasConcept C151730666 @default.
• W4283382900 hasConcept C2776305933 @default.
• W4283382900 hasConcept C2776694085 @default.
• W4283382900 hasConcept C2776755627 @default.
• W4283382900 hasConcept C2779429289 @default.
• W4283382900 hasConcept C2780775027 @default.
• W4283382900 hasConcept C71924100 @default.
• W4283382900 hasConcept C86803240 @default.
• W4283382900 hasConcept C87355193 @default.
• W4283382900 hasConceptScore W4283382900C121332964 @default.
• W4283382900 hasConceptScore W4283382900C126322002 @default.
• W4283382900 hasConceptScore W4283382900C141071460 @default.
• W4283382900 hasConceptScore W4283382900C142424586 @default.
• W4283382900 hasConceptScore W4283382900C146357865 @default.
• W4283382900 hasConceptScore W4283382900C151730666 @default.
• W4283382900 hasConceptScore W4283382900C2776305933 @default.
• W4283382900 hasConceptScore W4283382900C2776694085 @default.
• W4283382900 hasConceptScore W4283382900C2776755627 @default.
• W4283382900 hasConceptScore W4283382900C2779429289 @default.
• W4283382900 hasConceptScore W4283382900C2780775027 @default.
• W4283382900 hasConceptScore W4283382900C71924100 @default.
• W4283382900 hasConceptScore W4283382900C86803240 @default.
• W4283382900 hasConceptScore W4283382900C87355193 @default.
• W4283382900 hasLocation W42833829001 @default.
• W4283382900 hasLocation W42833829002 @default.
• W4283382900 hasLocation W42833829003 @default.
• W4283382900 hasOpenAccess W4283382900 @default.
• W4283382900 hasPrimaryLocation W42833829001 @default.
• W4283382900 hasRelatedWork W1973891791 @default.
• W4283382900 hasRelatedWork W2007761215 @default.
• W4283382900 hasRelatedWork W2013746871 @default.
• W4283382900 hasRelatedWork W2040492280 @default.
• W4283382900 hasRelatedWork W2124197615 @default.
• W4283382900 hasRelatedWork W2380296678 @default.
• W4283382900 hasRelatedWork W2403834487 @default.
• W4283382900 hasRelatedWork W2465559960 @default.
• W4283382900 hasRelatedWork W4224443308 @default.
• W4283382900 hasRelatedWork W2427250343 @default.
• W4283382900 hasVolume "6" @default.
• W4283382900 isParatext "false" @default.
• W4283382900 isRetracted "false" @default.
• W4283382900 workType "article" @default.